7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Tango Therapeutics Inc
(NASDAQ:TNGX) 

TNGX stock logo

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine pho...

Sector: REAL ESTATE & CONSTRUCTION
Industry: BLANK CHECKS

Share this website to your friends
Tango Therapeutics Days Payable Outstanding ttm (DPO)
202308 202309 202310 202311 202312 202401 202402 202403 202404 034.6169.22103.83138.43173.04207.65242.26
Tango Therapeutics Op Cashflow Per Share ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.22-1.05-0.87-0.7-0.52-0.35-0.170
Tango Therapeutics Free Cashflow Per Share ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.28-1.09-0.91-0.73-0.55-0.36-0.180
Tango Therapeutics Cash Per Share ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 00.531.061.592.122.653.183.71
Tango Therapeutics P/S ratio ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 0510.0115.0120.0125.0230.0235.02
Tango Therapeutics (GAAP) P/E ratio ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 -12.78-10.96-9.13-7.31-5.48-3.65-1.830
Tango Therapeutics P/B ratio ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 00.671.352.022.73.374.054.72
No extra charts and metrics for this ticker.